EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated In Silico Profiling of Chelidonium majus Alkaloids Identifies Potential Anti-Melanoma Candidates

Catalina Mares, Andra-Maria Paun, Maria Mernea, Stefania-Nicola Tatarus, Bogdan Mihai Cristea, Ioana Cristina Marinas, Speranta Avram

Processes · 28.03.2026 · 14 (7) · 1099

DOI: 10.3390/pr14071099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Processes, online erschienen am 28.03.2026. Verfasst von Catalina Mares und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Romanian National Authority for Scientific Research, CNCS—UEFISCDI.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma remains a highly aggressive malignancy, particularly in advanced metastatic stages where therapeutic options are limited. Natural compounds provide a structural basis for discovering novel anticancer agents. In this study, we employed an integrated in silico approach to evaluate the pharmacokinetic properties, toxicity profiles, and molecular targets of key alkaloids from Chelidonium majus, including berberine, sanguinarine, chelerythrine, chelidonine, protopine, umbelliferone and coptisine. ADME/T predictions (SwissADME and DeepPK) revealed favorable drug-likeness and oral bioavailability for most compounds, with berberine exhibiting the most balanced safety and absorption profile. All compounds demonstrated high intestinal absorption (>99%) and implicated key melanoma targets, including APE1/Ref-1, CXCR4, CCR2, TLR8, galectin-3, and VEGFR2. These molecules represent valuable templates for the development of melanoma therapies. Among the tested compounds, chelidonine emerged as a potential APE1 inhibitor, exhibiting the highest binding affinity and forming specific interactions within the enzyme’s catalytic site, suggesting its potential as a DNA repair-targeted agent in melanoma. These findings support the further exploration of natural alkaloids, including structural optimization or advanced formulation strategies, to enhance safety, bioavailability, and therapeutic efficacy in melanoma.

Förderung

  • Romanian National Authority for Scientific Research, CNCS—UEFISCDI

Zitieren

APA

Mares, C., Paun, A., Mernea, M., Tatarus, S., Cristea, B. M., Marinas, I. C., & Avram, S. (2026). Integrated In Silico Profiling of Chelidonium majus Alkaloids Identifies Potential Anti-Melanoma Candidates. Processes, 14(7), 1099. https://doi.org/10.3390/pr14071099

Vancouver

Mares C, Paun A, Mernea M, Tatarus S, Cristea BM, Marinas IC, et al. Integrated In Silico Profiling of Chelidonium majus Alkaloids Identifies Potential Anti-Melanoma Candidates. Processes. 2026;14(7):1099. doi:10.3390/pr14071099

BibTeX
@article{Mares2026,
  author = {Mares, Catalina and Paun, Andra-Maria and Mernea, Maria and Tatarus, Stefania-Nicola and Cristea, Bogdan Mihai and Marinas, Ioana Cristina and Avram, Speranta},
  title = {Integrated In Silico Profiling of Chelidonium majus Alkaloids Identifies Potential Anti-Melanoma Candidates},
  journal = {Processes},
  year = {2026},
  volume = {14},
  number = {7},
  pages = {1099},
  doi = {10.3390/pr14071099}
}
Kostenlos starten →